fda glp-1 warning letters september 2025 Issues 30 to Telehealth Firms Over Misleading Compounded Marketing U.S. FDA | The American

The clinical evidence establishes unprecedented therapeutic efficacy across established indications, with newer multi-receptor agonists achieving HbA1c reductions exceeding 2.0% in diabetes, weight loss approaching 24% in obesity that rivals bariatric surgery outcomes, and cardiovascular protection demonstrating consistent 1420% MACE reduction with emerging benefits in heart failure with preserved ejection fraction

Furthermore, we could get some information on the effect of GLP-1 RAs on cardiovascular outcomes through a few retrospective studies published in the literature [289899100101]

Moreover, semaglutide GLP-1 offers benefits beyond appetite control

Is GLP-1 Peptide Therapy Right for You

Wegovy Wegovy contains the same active ingredient as Ozempic but in different dose strengths

The Triple Agonist Mechanism Explained Retatrutide is a single-molecule triple agonist that simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon